Coloplast delivered 8% organic growth and EBIT increased by 13% to DKK 1,472m, corresponding to an EBIT margin of 31%, in the first quarter of the 2019/20 financial year. The company maintains its financial guidance for 2019/20.

Coloplast delivered 8% organic revenue growth in the first three months of the 2019/20 financial year, while reported growth in Danish kroner was up by 9% to DKK 4,712m.

EBIT amounted to DKK 1,472m, a 13% increase in DKK, corresponding to an EBIT-margin of 31% against 30% last year. ROIC after tax and before special items was 47% against 44% in the same period last year.

  • “We continue to deliver an organic revenue growth that is twice the market growth, driven by solid growth rates across all geographical regions and business areas. I would like to highlight our strong performance in Emerging Markets driven by China, Latin America, and Russia. Also, our Wound & Skin Care business delivered a good quarter driven by the Biatain® Silicone portfolio in Europe. In other words, we are off to a good start to the year,” says Coloplast CEO Kristian Villumsen. 

Organic growth rates by business area were 9% in Ostomy Care, 6% in Continence Care, 9% in Interventional Urology, and 10% in Wound & Skin Care. A comprehensive price reform in France adversely affected the growth performance in the Continence Care business.

Looking at sales by geography, the European markets contributed with 5% growth, Other developed markets delivered 10% revenue growth, while Emerging Markets provided a 16% increase.

Coloplast continues to invest in growth
Incremental investments of up to 2% of revenue were made in the first quarter into sales and marketing initiatives across multiple markets and business areas.

  • “We are investing across regions with a clear focus on China, our Emerging Markets, the US, and the UK. These markets hold great potential, and our ambition is to continue to take market share, while raising the standard of care for our users,” says Kristian Villumsen.

Coronavirus outbreak in China
Coloplast is monitoring the Coronavirus outbreak in China closely and taking all necessary precautions to keep the company’s 2,000 employees in Zhuhai and Beijing safe. Coloplast is collaborating fully with the Chinese authorities, and the company has, in collaboration with the authorities, donated Wound Care and Ostomy Care products to the Red Cross organisation in the Hubei Province.

Financial guidance for 2019/20
Coloplast continues to expect organic revenue growth of 7-8% at constant exchange rates and a reported growth in DKK of 7-8%. Coloplast continues to expect an EBIT margin of ~31% at constant exchange rates and a reported EBIT margin of ~31% in DKK.

The financial impact of the situation in China is uncertain. The company’s full-year guidance assumes that the situation normalises during Q2.

CONTACTS
Lina Danstrup
Senior Media Relations Manager, Corporate Communications
+45 49 11 26 07
dklina@coloplast.com

Ellen Bjurgert
Vice President, Investor Relations
+45 49 11 33 76
dkebj@coloplast.com

Financial highlights and key ratios (DKKm)2019/20
Q1		2018/19
Q1		Change
Revenue4,7124,3219%
EBIT1,4721,29713%
EBIT margin31%30% 
Profit for the period1,09299110%


Sales performance by business area
(DKKm)		2019/20
Q1		2018/19
Q1		Organic growthReported growth
Ostomy Care1,9071,7369%10%
Continence Care1,6861,5796%7%
Urology Care5354799%12%
Wound & Skin Care58452710%11%
Revenue4,7124,3218%9%


Financial guidance

 		Guidance for 2019/20Guidance for 2019/20 (DKK)
Sales growth7-8% (organic)7-8%
EBIT margin~31% (at constant exchange rates)~31%
Capital expenditure-~850
Tax rate-~23%

Attachment

  • 2019_2020_Q1_PM_ENG

© OMX, source OMX